Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.
Chiarini F, Lonetti A, Teti G, Orsini E, Bressanin D, Cappellini A, Ricci F, Tazzari PL, Ognibene A, Falconi M, Pagliaro P, Iacobucci I, Martinelli G, Amadori S, McCubrey JA, Martelli AM. Chiarini F, et al. Among authors: orsini e. Oncotarget. 2012 Dec;3(12):1615-28. doi: 10.18632/oncotarget.762. Oncotarget. 2012. PMID: 23271044 Free PMC article.
Therapeutic targeting of CK2 in acute and chronic leukemias.
Buontempo F, McCubrey JA, Orsini E, Ruzzene M, Cappellini A, Lonetti A, Evangelisti C, Chiarini F, Evangelisti C, Barata JT, Martelli AM. Buontempo F, et al. Among authors: orsini e. Leukemia. 2018 Jan;32(1):1-10. doi: 10.1038/leu.2017.301. Epub 2017 Sep 27. Leukemia. 2018. PMID: 28951560 Free PMC article. Review.
PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors.
Lonetti A, Cappellini A, Spartà AM, Chiarini F, Buontempo F, Evangelisti C, Evangelisti C, Orsini E, McCubrey JA, Martelli AM. Lonetti A, et al. Among authors: orsini e. Oncotarget. 2015 Apr 30;6(12):10399-414. doi: 10.18632/oncotarget.3295. Oncotarget. 2015. PMID: 25871383 Free PMC article.
Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.
Buontempo F, Orsini E, Lonetti A, Cappellini A, Chiarini F, Evangelisti C, Evangelisti C, Melchionda F, Pession A, Bertaina A, Locatelli F, Bertacchini J, Neri LM, McCubrey JA, Martelli AM. Buontempo F, et al. Among authors: orsini e. Oncotarget. 2016 Jan 12;7(2):1323-40. doi: 10.18632/oncotarget.6361. Oncotarget. 2016. PMID: 26593250 Free PMC article.
Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling.
Buontempo F, Orsini E, Martins LR, Antunes I, Lonetti A, Chiarini F, Tabellini G, Evangelisti C, Evangelisti C, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Cappellini A, Barata JT, Martelli AM. Buontempo F, et al. Among authors: orsini e. Leukemia. 2014 Mar;28(3):543-53. doi: 10.1038/leu.2013.349. Epub 2013 Nov 20. Leukemia. 2014. PMID: 24253024
Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting.
Chiarini F, Lonetti A, Evangelisti C, Buontempo F, Orsini E, Evangelisti C, Cappellini A, Neri LM, McCubrey JA, Martelli AM. Chiarini F, et al. Among authors: orsini e. Biochim Biophys Acta. 2016 Mar;1863(3):449-463. doi: 10.1016/j.bbamcr.2015.08.015. Epub 2015 Sep 1. Biochim Biophys Acta. 2016. PMID: 26334291 Free article. Review.
144 results